Holding(s) in Company

 

Notification of major interests in shares

 

LONDON, 28 May 2013 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK), the fast growing multinational pharmaceuticals group, announces as follows:

 

1

Identity of the issuer or the underlying issuer of existing shares to which the voting rights are attached

Hikma Pharmaceuticals PLC

 

 

2	Reason for the notification
	An acquisition or disposal of voting rights	Yes
	An acquisition or disposal of financial instruments which may result in the acquisition of shares already issues to which voting rights are attached	No
	An event changing the breakdown of voting rights	No
	Other (please specify): Compliance with the Transparency Directive	No

 

 

3	Full name of the person subject to the notification obligation						FMR LLC
4	Full name of shareholders						See attached schedule
5	Date of the Transaction (and date on which the threshold crossed is reached differently)						24 May 2013
6	Date on which the issuer notified						28 May 2013
7	Threshold that is crossed						5%
8	Notified details						See A, B & C below
A. Voting rights attached to shares
Class type of shares (if possible using the ISIN code)		Situation previous to the triggering transaction		Resulting situation after the triggering transaction
		Number of shares	Number of voting rights	Number of shares		Number of voting rights			% of voting rights
				Direct	Indirect	Direct		Indirect	Direct	Indirect
Ordinary Shares (0.10 GBP) GB00B0LCW083		9,981,498	9,981,498	0	9,873,932	0		9,873,932	4.99	9,981,498

 

B. Qualifying Financial instruments
Resulting situation after the triggering transaction
Type of financial instrument	Expiration Date	Exercise/Conversion Period/Date	Number of voting rights that may be acquired if the instrument if exercised/converted	% of voting rights
-	-	-	-	-

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument	Exercise Price	Expiration Date	Exercise/Conversion Period/Date	Number of voting rights instrument refers to	% of voting rights
					Nominal	Delta
-	-	-	-	-	-	-

 

Total A+B+C
Number of Voting rights	% of voting rights
9,873,932	4.99%

 

9	Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable

 

Proxy Voting
10	Name of the proxy holder	Custodian Advisor Total BANK OF NEW YORK MELLON PGATC-PYRAMIS GLOBAL ADVISORS TRUST COMPANY 444,863 BROWN BROTHERS HARRIMAN AND CO PGALLC-PYRAMIS GLOBAL ADVISORS, LLC. 77,902 PGATC-PYRAMIS GLOBAL ADVISORS TRUST COMPANY 1,470,792 CIBC MELLON TRUST (C) PGALLC-PYRAMIS GLOBAL ADVISORS, LLC. 21,864 JPMORGAN CHASE BANK FMR-FIDELITY MANAGEMENT AND RESEARCH 2,895,828 PGALLC-PYRAMIS GLOBAL ADVISORS, LLC. 303,907 PGATC-PYRAMIS GLOBAL ADVISORS TRUST COMPANY 41,532 MELLON BANK NA (C) PGALLC-PYRAMIS GLOBAL ADVISORS, LLC. 458,294 PGATC-PYRAMIS GLOBAL ADVISORS TRUST COMPANY 519,332 NATIONAL BANK TRUST (C) FIDELITY INVTS-FIDELITY INVESTMENTS CANADA 22,024 NORTHERN TRUST CO (C) FMR-FIDELITY MANAGEMENT AND RESEARCH 1,964,745 PGATC-PYRAMIS GLOBAL ADVISORS TRUST COMPANY 309,862 RBC INVESTOR SERV ZURICH (C) PGA UK LTD-PYRAMIS GLOBAL ADVISORS UK LTD 73,004 ROYAL TRUST- TORONTO (C) FIDELITY INVTS-FIDELITY INVESTMENTS CANADA 59,478 PGALLC-PYRAMIS GLOBAL ADVISORS, LLC. 17,862 STATE STREET BANK AND TR CO FMR-FIDELITY MANAGEMENT AND RESEARCH 213,380 PGALLC-PYRAMIS GLOBAL ADVISORS, LLC. 491,336 PGATC-PYRAMIS GLOBAL ADVISORS TRUST COMPANY 432,657 SAI-STRATEGIC ADVISERS GROUP 30,113 US BANK NA (C) PGALLC-PYRAMIS GLOBAL ADVISORS, LLC. 25,157 Grand Total 9,873,932
11	Number of voting rights proxy holder will cease to hold	N/A
12	Date on which proxy holder will cease to hold voting rights	N/A

 

13	Additional Information
14	Contact name:	Peter Speirs, Company Secretary
15	Contact telephone number:	020 7399 2772

 

- ENDS -

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.  In 2012, Hikma achieved revenues of $1,108.7 million and profit attributable to shareholders of $100.3 million.